EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Aurinia Pharmaceuticals's enterprise value is $856.7 Mil.
Aurinia Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 was $247.3 Mil. Therefore, Aurinia Pharmaceuticals's EV-to-Revenue for today is 3.46.
The historical rank and industry rank for Aurinia Pharmaceuticals's EV-to-Revenue or its related term are showing as below:
AUPH'
s EV-to-Revenue Range Over the Past 10 Years
Min: 1.89 Med: 297.87 Max: 5786.47
Current: 3.46
During the past 13 years, the highest EV-to-Revenue of Aurinia Pharmaceuticals was 5786.47. The lowest was 1.89. And the median was 297.87.
AUPH's EV-to-Revenue is ranked better than 67.94% of 998
companies
in the Biotechnology industry
Industry Median: 7.38
vs AUPH: 3.46
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Aurinia Pharmaceuticals's EV-to-Revenue
For the Biotechnology subindustry, Aurinia Pharmaceuticals's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aurinia Pharmaceuticals's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Aurinia Pharmaceuticals's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Aurinia Pharmaceuticals's EV-to-Revenue falls into.
Aurinia Pharmaceuticals's current Enterprise Value is $856.7 Mil.
Aurinia Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $247.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aurinia Pharmaceuticals's share price for today is $8.15.
Aurinia Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.71.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aurinia Pharmaceuticals EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Aurinia Pharmaceuticals's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
AUPH has been successfully added to your 